GRO Biosciences

GRO Biosciences leverages synthetic biology to expand the amino acid alphabet and develop protein therapeutics. Its lead program, ProGly-Uricase, targets refractory gout by preventing the formation of anti-drug antibodies. The company's platform is adaptable to various immunogenic therapies and autoimmune diseases.

Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $60.3M

Date: 19-Jul-2024

Investors: Atlas Venture, Access Biotechnology, Leaps by Bayer, Redmile Group, Digitalis Ventures, Innovation Endeavors

Markets: Biotechnology, Pharmaceuticals, Synthetic Biology, Health Diagnostics, Medical, Therapeutics

HQ: Boston, Massachusetts, United States

Founded: 2016

Website: https://www.grobio.com/

LinkedIn: https://www.linkedin.com/company/grobio/

Twitter: https://twitter.com/gro_bio

Instagram: https://www.instagram.com/gro_bio/